With a market capitalization approaching the $1 trillion mark, Eli Lilly is engaged in a close competitive race with Novo Nordisk for dominance in the obesity treatment sector. Market researchers ...

The Business in brief section below includes short stories on a fundraising by Medra, which promises AI and machines that can autonomously run experiments from end to end, and a fundraising by ChemLex ...

ODBM is one of 60 organizations from across the United States that have received grants through the initiative since 2024.

Grand View Research found that North America accounts for the largest revenue share, with more than 75% of the GLP-1 agonists market. While other alternative obesity interventions exist, including ...

BlackRock Health Sciences Trust is a Buy for income investors, offering an 8% yield, NAV discount, and resilient healthcare ...

If you don't have time to study the world of stock investments, consider an exchange-traded fund (ETF) that’s focused on ...

No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

This week's dividend activity included increased payouts from Eli Lilly (LLY) and Mastercard (MA) as well as declarations ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

The Harbor Health Care ETF MEDI is now three years old and has performed so well that it has been rated five stars (the highest rating) within Morningstar's U.S. Fund Health category. The ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.